Seagen Stock Price

3.45 (2.6%)
Upgrade to Real-Time
Regular Market
Volume 54,635
Bid Price 135.72
Ask Price 136.42
News -
Day High 136.00


52 Week Range


Day Low 133.02
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Seagen Inc SGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
3.45 2.6% 136.00 09:37:50
Open Price Low Price High Price Close Price Prev Close
134.34 133.02 136.00 132.55
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
145 54,635 $ 134.45 $ 7,345,827 - 129.61 - 199.00
Last Trade Time Type Quantity Stock Price Currency
09:38:41 1 $ 136.40 USD


Draw Mode:

Seagen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 24.87B 182.86M 67.29M $ 2.18B $ -950.06M 3.30 -74.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -553.09k 1.20%

more financials information »

Seagen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week140.00140.835129.61133.831,013,763-4.00-2.86%
1 Month157.02161.00129.61144.91692,289-21.02-13.39%
3 Months173.56192.7867129.61159.55862,485-37.56-21.64%
6 Months144.69192.7867129.61160.03793,775-8.69-6.01%
1 Year189.22199.00129.61156.28892,860-53.22-28.13%
3 Years72.30213.9462.90132.38972,95663.7088.11%
5 Years59.36213.9445.31103.88966,45776.64129.11%

Seagen Description

Seagen Inc. (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220120 14:54:04